Aspira Women’s Health (NASDAQ:AWH) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued to investors on Monday morning. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners decreased their price target on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Trading Up 1.9 %

NASDAQ AWH opened at $0.78 on Monday. The business has a fifty day simple moving average of $0.94 and a 200 day simple moving average of $1.78. Aspira Women’s Health has a 12 month low of $0.74 and a 12 month high of $6.01. The firm has a market capitalization of $9.68 million, a P/E ratio of -0.54 and a beta of 1.47.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The firm had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same period in the previous year, the business earned ($0.28) earnings per share. As a group, sell-side analysts predict that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. 12.19% of the stock is owned by institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.